Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 12, 2026

Retiring with $1.2 Million? Here's How to Avoid Running Out of Savings

View original at nasdaq.com
Retiring with $1.2 Million? Here's How to Avoid Running Out of Savings Key Points Even though $1.2 million is a nice amount of money, it needs to be managed carefully…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • For each year a claim is delayed past full retirement age until age 70, Social Security benefits get a permanent 8% boost.

    60% confidence
  • More conservative investors, or those retiring in their 50s, may need to stick to a 3% or 3.5% withdrawal rate; those retiring later may be able to take larger percentage withdrawals.

    60% confidence
  • A little-known Social Security claiming strategy could pay retirees as much as $23,760 more per year.

    60% confidence
  • People born in 1960 or later can collect full monthly Social Security benefits at age 67.

    60% confidence
  • Keeping one to three years' worth of planned expenses in cash allows retirees to leave investments untouched during downturns and cover unplanned expenses.

    60% confidence
  • The Motley Fool cannot and does not provide personalized investing or financial advice; the information is for informational and educational purposes only.

    60% confidence
  • For a fairly equal mix of stocks and bonds and a 20- to 30-year retirement, the 4% withdrawal rule might work.

    60% confidence

Data points we hold from this source

Social Security Administration · maximum claiming strategy bonus23760 USD
Social Security Administration · full retirement age67 years
Social Security Administration · recommended safe withdrawal rate4 percent
Social Security Administration · delayed retirement credit rate8 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com